



## PRESS RELEASE

### **Adocia announces the termination of its liquidity agreement with DSF MARKETS**

**Lyon, France, May 5, 2014** - Adocia (Euronext Paris: FR0011184241 – ADOC) announces that it has terminated, on April 30, 2014, the liquidity agreement entrusted to DSF Markets (formerly named BIL Finance).

The following assets appeared on the liquidity account as at April 30, 2014:

- 15,026 shares of Adocia and
- 502,312.46 euros in cash.

As the reminder, the following assets appeared on the liquidity account at the latest report dated December 31, 2013:

- 40,326 shares of Adocia and
- 215,305.78 euros in cash.

As a reminder, the liquidity agreement was concluded on March 14, 2012 with an initial contribution amounting to 500,000 euros.

#### **About Adocia:**

##### **To be a global leader for delivery of insulins and therapeutic proteins**

Adocia is a biotech company specialized in the development of innovative formulations of already-approved therapeutic proteins with a strong expertise on insulins. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Adocia successfully completed two Phases I and II studies of the formulation of a fast-acting human insulin, two Phases I and II studies of an ultra-fast acting insulin lispro and one Phase I/II on a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Dose-escalating Phase IIa studies are planned for these three products in 2014.

Adocia has also obtained positive results on a Phase I/II study of a diabetic-foot-ulcer-healing product based on PDGF-BB.

Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of various chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.

### **To fight cancer by targeting oncology treatments**

DriveIn<sup>®</sup> is a nanotechnology which is remarkably efficient in carrying active molecules and delivering them into solid tumors. This new platform is an exceptional opportunity to enter the oncology market by improving the efficacy of already approved treatments and of proprietary molecules.

### **'Innovative medicine for everyone, everywhere'**

Adocia's therapeutic innovations aim at bringing solutions in a profoundly changing global pharmaceutical and economic context, characterized by an increased prevalence and impact of targeted pathologies, a growing and ageing population, a need to control public health expenditures and an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index.

For more information: <http://www.adocia.com>

#### **Contact**

Gerard Soula - [contactinvestisseurs@adocia.com](mailto:contactinvestisseurs@adocia.com)

Chairman and CEO of Adocia

Tel.: +33 4 72 610 610



#### **Disclaimer**

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 'Risk Factors' section of the Reference Document registered by the Autorite des Marches Financiers on April 25, 2013 under number R13-017 (a copy of which is available on <http://www.adocia.com>) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.